- In August 2022, Roche launched the Benchmark Ultra Plus System for cancer diagnostics. This advanced system aims to enhance the precision and efficiency of cancer detection by providing more accurate and faster test results. It is designed to help healthcare providers better understand and monitor cancer progression through improved biomarker analysis. The system’s ability to detect cancer earlier, monitor treatment responses, and personalize patient care will significantly benefit both clinicians and patients. By delivering enhanced diagnostic insights, it supports better clinical decision-making, ultimately improving patient outcomes in cancer care
- In November 2022, Roche received FDA approval for the VENTANA FOLR1 (FOLR1-2.1) RXDx Assay. This assay is designed to detect FOLR1 (Folate Receptor Alpha) expression in cancer patients, specifically for those with non-small cell lung cancer (NSCLC). By identifying patients who may benefit from targeted therapies, the assay aims to personalize treatment options, improving outcomes for individuals with FOLR1-expressing tumors. This approval represents a significant advancement in molecular testing, allowing healthcare providers to offer more precise and effective treatment strategies, ultimately enhancing patient care in oncology
